Impact of Probiotics on Neuropathy Induced by Adjuvant Chemotherapy in Patients With Colon Cancer.

Inclusion Criteria:

* Patient ≥ 18 years
* Patient with histologically confirmed stage III adenocarcinoma colon cancer with curative resection
* Patient with an indication to start adjuvant oxaliplatin-based chemotherapy (FOLFOX 4 or XELOX regimen)
* ECOG performance status score of 0 or 1
* Patient must consent to allow the collection of fecal and blood samples during study for further ancillary studies
* Screening laboratory values must meet the following criteria:
* Neutrophils ≥ 1500/ mm³; Platelets ≥ 100 000/ mm³; Hemoglobin ≥ 9.0 g/dL
* Bilirubin ≤ 1.5 x ULN, AST and ALT ≤ 3 x ULN
* Serum creatinine ≤ 1.5 x ULN or measured or calculated creatinine ≥ 50 ml/min clearance (CrCl) (using the Cockcroft-Gault formula)
* Patient with French language comprehension
* Female subject of childbearing potential must have a negative urine or serum pregnancy test within 7 days before study probiotics supplementation start
* Patient in reproductive age must be willing to use adequate contraception during study probiotics supplementation
* Patient affiliated to an appropriate social security system
* Patient has signed informed consent obtained before to any study specific procedures

Enclusion Criteria:

* Patient with any distant metastasis
* Patient with current peripheral neuropathy of any grade or ongoing treatment prescribed to prevent or treat peripheral neuropathy
* Patient with hypersensitivity to any ingredients in the composition of the multi-strain formulation and/or maltose
* Patient with history of acute pancreatitis
* Patient seriously immunosuppressed
* Patient with history of other malignancy within the previous 3 years (except for appropriately treated in-situ cervix carcinoma and non-melanoma skin carcinoma)
* Patient using of probiotics or antibiotic treatments within one month before inclusion
* Patient with chronic inflammatory gastro-intestinal disease
* Patient with uracilemia ≥ 16 ng/ml
* Patient with QT/QTc \> 450 msec for men and \> 470 msec for women
* Patient with active infection requiring systemic therapy
* Patient with personality disorder or any other known progressive psychiatric pathology
* Patient with neurological previous history with ongoing symptoms (sequelae of head trauma, stroke, multiple sclerosis, epilepsy, neurodegenerative pathology, etc.)
* Patient with dependence on alcohol and / or drugs
* Pregnant or lactating woman
* Simultaneous participation in another clinical study that may compromise the conduct of this study.
* Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
* Patient deprived of liberty or placed under the authority of a tutor